Bifunctional alkylating agent-mediated MGMT-DNA cross-linking and its proteolytic cleavage in 16HBE cells

Toxicology and Applied Pharmacology 305 (2016) 267–273

Contents lists available at ScienceDirect

Toxicology and Applied Pharmacology journal homepage: www.elsevier.com/locate/ytaap

Bifunctional alkylating agent-mediated MGMT-DNA cross-linking and its proteolytic cleavage in 16HBE cells Jin Cheng, Feng Ye, Guorong Dan, Yuanpeng Zhao, Bin Wang, Jiqing Zhao, Yan Sai, Zhongmin Zou ⁎ Institute of Toxicology, School of Preventive Medicine, the Third Military Medical University, 30 Gaotanyan Avenue, Shapingba District, Chongqing 400038, China

a r t i c l e

i n f o

Article history: Received 22 December 2015 Revised 8 June 2016 Accepted 20 June 2016 Available online 21 June 2016 Key words: MGMT DNA damage and repair DNA-protein cross-link Bifunctional alkylating agent Nitrogen mustard Proteolysis

a b s t r a c t Nitrogen mustard (NM), a bifunctional alkylating agent (BAA), contains two alkyl arms and can act as a crosslinking bridge between DNA and protein to form a DNA-protein cross-link (DPC). O6-methylguanine–DNA methyltransferase (MGMT), a DNA repair enzyme for alkyl adducts removal, is found to enhance cell sensitivity to BAAs and to promote damage, possibly due to its stable covalent cross-linking with DNA mediated by BAAs. To investigate MGMT-DNA cross-link (mDPC) formation and its possible dual roles in NM exposure, human bronchial epithelial cell line 16HBE was subjected to different concentrations of HN2, a kind of NM, and we found mDPC was induced by HN2 in a concentration-dependent manner, but the mRNA and total protein of MGMT were suppressed. As early as 1 h after HN2 treatment, high mDPC was achieved and the level maintained for up to 24 h. Quick total DPC (tDPC) and γ-H2AX accumulation were observed. To evaluate the effect of newly predicted protease DVC1 on DPC cleavage, we applied siRNA of MGMT and DVC1, MG132 (proteasome inhibitor), and NMS-873 (p97 inhibitor) and found that proteolysis plays a role. DVC1 was proven to be more important in the cleavage of mDPC than tDPC in a p97-dependent manner. HN2 exposure induced DVC1 upregulation, which was at least partially contributed to MGMT cleavage by proteolysis because HN2-induced mDPC level and DNA damage was closely related with DVC1 expression. Homologous recombination (HR) was also activated. Our findings demonstrated that MGMT might turn into a DNA damage promoter by forming DPC when exposed to HN2. Proteolysis, especially DVC1, plays a crucial role in mDPC repair. © 2016 Published by Elsevier Inc.

1. Introduction Initially, nitrogen mustards (NM) are used as an important military vesicant agent. NM can cause skin inflammation, blisters, and ulcers, as well as eye and respiratory tract damage, with no effective treatment. One of the commonly accepted mechanisms of NMs that causes tissue damage is an active DNA alkylating ability. As a kind of bifunctional alkylating agent (BAA), NM contains two functional N-chloroethyl groups, which can react with nucleophilic groups within DNA or proteins to cause a DNA–DNA or DNA–protein cross-link (DPC) (Loeber et al., 2009). Based on the alkylating effect on biomolecules, many kinds of NM derivatives including N-methyl-2.2-di(chloroethyl)amine (HN2), also called mechlorethamine, chlorambucil, and melphalan are widely used clinically against various tumors including lymphoma, leukemia, and multiple myeloma. However, little is known about the

Abbreviations: NM, nitrogen mustard; MGMT, O6-methylguanine–DNA methyltransferase; BAA, bifunctional alkylating agents; DPC, DNA-protein cross-link; DSB, double strand break; SSB, single strand break; NER, nucleotide excision repair; HR, homologous recombination. * Corresponding author. E-mail address: [email protected] (Z. Zou).

http://dx.doi.org/10.1016/j.taap.2016.06.022 0041-008X/© 2016 Published by Elsevier Inc.

details of DPCs in terms of their levels or their relationship with DNA damage repair. Various endogenous and exogenous agents including irradiation, chemotherapy drugs, and cytotoxic agents can induce DNA damage (Loeber et al., 2009). DPC is a type of DNA damage when a protein covalently binds to DNA to form an adduct (Barker et al., 2005). Compared with DNA damages like double-strand break (DSB) and single-strand break (SSB), much less attention has been paid to DPCs and a poor understanding remains because of the low abundance and structural complexity of DPCs (Wong et al., 2012). In fact, bulky adducts and helixdistorting lesions have lethal effects on DNA replication, transcription, recombination, and chromatin remodeling (Barker et al., 2005). In addition, DPC lesions can prevent DNA repair proteins from binding to the damaged nucleobase, thus promoting subsequent failure of the DNA repair process. Both of these effects may lead to the cytotoxicity and genotoxicity of DPCs. However, because of the difficulty in establishing a model uniquely inducing DPC rather than other types of DNA damage and in accurately detecting different kinds of DPCs, the mechanisms of formation, repair, and effect on cell activity of DPCs are not yet well understood (Stingele et al., 2015; Stingele and Jentsch, 2015). O6-methylguanine–DNA methyltransferase (MGMT), also called O6alkylguanine-DNA alkyltransferase (AGT), is a DNA-repair protein that transfers alkyl adducts from the O6-position of guanine to the 145

268

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273

cysteine residue (Cys145) of MGMT meanwhile irreversibly inactivating itself. Then, the inactivated MGMT is ubiquitinated and degraded by proteasomes (Cabrini et al., 2015). Normally, the MGMT-mediated irreversible alkyl transfer prevents gene mutations and cell apoptosis resulting from alkylating and cross-linking damages commonly induced by environmental toxicants (Srivenugopal et al., 2016). On the other hand, because of the capability of alkyl adduct removal, MGMT may cause drug resistance of tumor cells to chemotherapy by upregulated MGMT expression. However, some recent studies find that MGMT may enhance the cytotoxicity and mutagenicity of several bis-electrophiles, which usually have two symmetrical reactive sites readily for substrate DNA or protein (Loeber et al., 2006; Kalapila and Pegg, 2010; Pegg, 2011). Definite evidence shows that DNA lesions are formed in NMtreated neurons (Kisby et al., 2009). Overexpressing MGMT in CHO cells can aggravate the cytotoxicity of bifunctional alkylating agents (Kalapila and Pegg, 2010; Pegg, 2011). It was proposed that MGMT increases the cytotoxic and mutagenic effects of NM and its analogues by reacting with one active arm of NM at the cysteine site of MGMT to form a half-mustard, which can either be cleaved via proteasome pathway or react further with DNA via another arm of MN to generate a MGMT-DNA cross-link (mDPC) (Pegg, 2011; Casorelli et al., 2012). We proposed that MGMT might play a different role in BAA-treated cells in addition to its original DNA repair function. Many DNA repair pathways are candidates for DPC repair. Nucleotide excision repair (NER) is widely involved in both bacteria and eukaryotes in removing cross-linked protein with low molecular weights (b11 kDa) (Nakano et al., 2007; Ide et al., 2011). Homologous recombination (HR) is also involved in some types of DPC (especially N 11 kDa) (Ide et al., 2011). The predominant pathway chosen by cells may also depend on the type of damage. For example, HR deletion caused the greatest sensitivity under low-dose, chronic exposure to formaldehyde, while NER conferred only low-to-moderate sensitivity under the same exposure. However, following high-dose acute exposure, NER conferred maximal survival, with little contribution of HR (de Graaf et al., 2009). Recently, a process of removing covalently linked proteins by proteolysis in a replication-dependent manner was revealed (Duxin et al., 2014; Stingele et al., 2014). Proteolysis is hypothesized to play a key role in DPC repair by enzymatic digestion. After reducing the size of adducted protein, the bulky protein yields a smaller substrate for canonical DNA repair pathways. Recently, Wss1 has been identified as a member of a protease family for DPC repair in yeast. Stingele et al. argue that DVC1 (DNA damage protein targeting VCP), also called Spartan (SprT-like domain-containing protein), could be a representative ortholog of Wss1 in mammals due to their sequence and motif homology. Primary data confirmed that DVC1 mediates DNA repair by ubiquitinating target proteins independent of HR (Stingele et al., 2014; Stingele et al., 2015). Up to now, the newly found DVC1 with its effect of proteolysis in DPC repair has not been reported. The rapid development of methods for protein labeling and immunodetection provides the possibility to directly detect DPC in living cells with high accuracy and specificity, even to detect a specific protein in the DPC complex (Shoulkamy et al., 2012; Kiianitsa and Maizels, 2013). In this study, harnessing the methodological advance, we focused on NM-induced DNA damage and DPC (mDPC) formation to reveal their characteristics, and then studied the repair manner of DPC. Our results demonstrated that the formation of MGMT-DNA complex in NM-treated cells showed a dose- and time-effect relationship and that proteolysis as well as HR was involved in DPC repair. 2. Materials and methods 2.1. Cell culture and treatment Human bronchial epithelial cell line 16HBE was cultured in MEM medium supplemented with 10% fetal calf serum with a seeding number of 1 × 106 per 60-mm dish. Two days later, cells with 80% confluence

were treated with HN2, a kind of NM (DB, China), which was freshly dissolved in PBS at a concentration of 10 mM. In dose-response experiment, cells were treated with HN2 at a final concentration of 20 μM, 50 μM, 100 μM, and 200 μM in culture medium for 1 h before being placed in normal medium. The concentration of HN2 in other experiments was 50 μM. For protein inhibition assay, 2 μM of proteasome inhibitor MG132 (Selleck, USA) and 0.5 μM of p97 inhibitor NMS-873 (Selleck, USA) were added after HN2 exposure and incubated for 3 h before the shift to normal culture medium. 2.2. Transient transfection Cells with a total number of 1 × 106 were seeded into a 60-mm dish. The next day, synthesized MGMT siRNA (5′AAGCTGGAGCTGTCTGGTTGT-3′) and DVC1 siRNA 5′UCAAGUACCACCUGUAUUA-3′ (Invitrogen, USA) were transfected to cells with Lipofectamine2000 (Invitrogen, USA) according to the protocol. Cells were treated with HN2 2 days after the transfection. 2.3. Cell lysis and DPC isolation Cell lysis and DPC isolation methods were referred to Kiianitsa's protocol with modification (Kiianitsa and Maizels, 2013). In brief, cells were lysed by adding DNAiso (TaKaRa, Japan) (not to exceed 2 × 106 cells per 1 ml lysis solution). Five minutes later, nucleic acids and DPC were precipitated by adding of 0.5 volume of 100% ethanol followed by centrifugation, and the precipitate was washed twice with 75% ethanol. The precipitate was resuspended in 200 μl TE buffer or Milli-Q water after completing ethanol volatilization, and DNA concentration quantified. 2.4. DNA quantification SYBR Green binds to double-stranded DNA (dsDNA) and the amount of dsDNA is reflected by detecting fluorescence intensity emitted by the dye. Standard DNA from calf thymus (Sigma, USA) was diluted with TE to a final concentration of 8 ng/μl, 4 ng/μl, 2 ng/μl, 1 ng/μl, and 0.5 ng/μl. DPC sample harvested from a 100-mm dish was diluted to 1:1000. Into each well of a 96-well plate, 100 μl calf thymus DNA or DPC sample was added followed by the addition of an equal volume of SYBR Green solution (Rebio, China). After 15 min of incubation in the dark, fluorescence intensity was measured and the DNA concentration of the DPC sample was calculated according to the standard curve determined by calf-thymus DNA. 2.5. FITC labeling and total-DPC (tDPC) measurement Shoulkamy's protocol with modification was carried out (Shoulkamy et al., 2012). In brief, 10 mM FITC stock solution in dimethylformamide was added to DPC solution (10 μg) to a final concentration of 0.1 mM and incubated at room temperature for 1 h to label the cross-linked proteins. The labeled DPC then was precipitated by 100% ethanol, and then washed twice with 75% ethanol, air dried, and dissolved in TE buffer. The fluorescence strength was measured on a fluorescence spectrophotometer to qualify the level of FITC-labeled protein. The loading amount of DPC samples could be adjusted according to the protein contents. 2.6. Immunological detection of mDPC The study method was based mainly on Kiianitsa's report (Kiianitsa and Maizels, 2013). Briefly, slot-blot wells were washed with TBS before use. Equal amounts of DNA samples in 200 μl were slot-blotted onto a nitrocellulose membrane with a vacuum according to the manufacturer's instruction of the slot blotter, then washed with TBS three times. The membrane was blocked with 1% BSA and incubated with anti-MGMT primary antibody (Santa Cruz, USA). The membrane

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273

was incubated with ECL substrate and the luminescent image was captured with Fusion Fx and the software FusionCapt Advance. The band intensity was quantified with Image J. 2.7. RT-PCR Total RNA was isolated from cells with TRIzol (Invitrogen, USA) and purified according to standard phenol-chloroform methods. Briefly, cells were lysed with 1 ml TRIzol per 6-well plate with end-over-end mixing, and 1/5 volume of chloroform was added. After 5 min standing and following centrifugation, an equal volume of isopropyl alcohol was added in supernatant. The mixture was incubated in −20 °C for 1 h, and RNA was precipitated by centrifugation. RNA was washed with 75% ethanol and resuspended in 20 μl DEPC water after completing ethanol volatilization. Two μg RNA samples were reverse transcribed to cDNA using a transcript II RT Kit (Tiangen, China), and PCR was carried out with following program: 95 °C for 90 s, then 30 cycles of 94 °C for 30 s, 57 °C for 30 s, and 72 °C for 60 s, ending with 72 °C for 5 min. PCR of the reference gene was carried out with 15 cycles. The PCR products were identified by agarose gel electrophoresis and visualized under UV light. 2.8. Western blot Methods were performed according to the standard procedure with nitrocellulose membrane. Mouse monoclonal anti-MGMT (Santa Cruz, USA) antibody was used at a dilution of 1:200, rabbit polyclonal antiDVC1 antibody (Abcam, USA), rabbit polyclonal anti-RAD51 antibody (Santa Cruz, USA), rabbit polyclonal anti-H2AX antibody (Santa Cruz, USA), mouse polyclonal anti-β-ACTIN antibody (Santa Cruz, USA) all were used at a dilution of 1:1000. The band intensity was captured and quantified in the same way as mDPC detection. All the band intensities of target proteins were adjusted by calculating the ratio to βACTIN. 3. Statistical analysis All the sample sizes are at least three. Experiment data were calculated by one-way ANOVA and presented as mean ± standard deviation. Bonferroni's analysis was used for post-hoc test. P value b 0.05 was considered as statistically significant. 4. Results 4.1. HN2 induced DPC and DSB Because vapor exposure via the respiratory system is an important route for vesicant injury, human bronchial epithelial cell line 16HBE was used as cell model for HN2 exposure in this study (Supplementary Fig. 1A). SYBR Green labeling was adopted to quantify DNA contents in DPC samples collected from HN2-treated cells by measuring

269

fluorescence intensity. Then, the total level of DPC (tDPC) in equal amounts of DNA from different DPC samples was comparatively analyzed based on FITC-labeled protein. As expected, similar to other biselectrophiles containing BAAs, HN2 significantly induced DPC formation, which was detectable as early as 1 h after the treatment, and maintained at a high level till 24 h (Fig. 1A). In addition, a strong increase of mRNA level and the protein phosphorylation of H2AX was also revealed 1–24 h after HN2 exposure (Fig. 1B), indicating increased DSB damage response of cells. The phosphorylation of H2AX (γ-H2AX), an instant response to DSB, was significantly boosted at 1 h after the insult (0.91 ± 0.01 vs. 0.45 ± 0.01), meanwhile the upregulation of H2AX mRNA, a process to synthesize new protein, occurred at 1 h (0.32 ± 0.01) and reached peak value at 24 h (0.66 ± 0.03 vs. 0.07 ± 0.01). 4.2. MGMT formed mDPC after HN2 treatment As a DNA repair enzyme, the normal function of MGMT is to remove alkyl adducts from the O6-position of guanine when DNA is suffered from alkylating damage. Because MGMT is irreversibly inactivated and degraded after accepting the alkyl adduct, de novo synthesis of MGMT protein as a supplement during DNA damage repair has been reported in the treatment of alkylating agents other than NM (Ueda et al., 2004). When the expression level of MGMT was detected after HN2 treatment, unexpectedly, the transcription of MGMT was almost completely inhibited at 1 h (0.29 ± 0.01 vs. 1.08 ± 0.01) and partially recovered at 6 h (0.83 ± 0.01) and 24 h (0.77 ± 0.01). Simultaneously, a significant decline of free MGMT protein at 24 h was evident (0.21 ± 0.03 vs. 0.36 ± 0.04) (Fig. 2A). An explanation for this paradox could be that cytoplasmic MGMT translocated to the nuclear compartment and was cross-linked by HN2. To confirm this presumption, we examined cellular mDPC levels after it was exposed to different concentration of HN2 by slot blot. It was found that the mDPC level elevated significantly along with the HN2 concentration. For the exposure of 0 μM, 20 μM, 50 μM, 100 μM, and 200 μM HN2, the band intensity of mDPC was 29.74 ± 0.44, 50.77 ± 2.55, 47.92 ± 3.14, 87.26 ± 5.85, and 88.91 ± 4.74, respectively (Fig. 2B), suggesting that the translocation of MGMT to the nuclear compartment in response to DNA alkylation was not disrupted, but unfortunately, these recruited MGMT became a substrate of HN2 in the nuclear compartment and finally became a component of DPC that could further recruit MGMT and other DNA repair proteins. As shown in the time-response relationship, mDPC was formed as early as 1 h (162.04 ± 3.69 vs. 120.19 ± 4.31) after HN2 exposure, and the level was still significantly higher than the control at 6 h (152.24 ± 6.27) and 24 h (153.65 ± 5.13) although slightly declined from the measurement at 1 h (Fig. 2C). Interestingly, the time-course changes of mDPC was consistent with γH2AX, suggesting a sound MGMT recruitment in response to H2AX phosphorylation. Because the cells were only subjected to transient HN2 challenge (1 h duration), the active HN2 would generally alkylate its favor

Fig. 1. HN2 induced DPC formation and DSB in 16HBE cells. (A) Cells were exposed to 50-μM HN2 for 1 h and cultured for 24 h. Proteins on an equal amount of isolated DNA were labeled by FITC and measured for fluorescence intensity. FITC labeled little cross-linked proteins in normal cells, but HN2 exposure strongly increases the tDPC amount at 1 h and 24 h. *P b 0.05 vs. control. (B) Both mRNA and proteins of γ-H2AX increased 1 h after HN2 exposure and continued to 24 h, which indicates a strong DSB.

270

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273

4.3. Proteolysis and HR took part in DNA repair

Fig. 2. The time- and dose-response relationship of MGMT in HN2-treated 16HBE. (A) The mRNA and protein expression of MGMT 1–24 h after 50-μM HN2 exposure. Cells were continuously cultured 1 h, 6 h, or 24 h after HN2 exposure. The mRNA and total protein level decreased significantly. (B) The amount of mDPC induced by different concentrations of HN2 at 24 h after exposure. The mDPC level increased coincidence with the concentration of HN2. (C) The amount of mDPC 1–24 h after HN2 exposure. (D) The amount of mDPC influenced by MGMT deletion after HN2 exposure. MGMT siRNA were transfected into cells 2 d before HN2 exposure. (E) MGMT protein level after siRNA transfection.

substrates within a short time as seen at 1 h and a much lower fraction of new DPC was induced thereafter by HN2. In this way, the mDPC levels detected in the following time points could indicate the clearance dynamics of the formed mDPC, which turn out to exist for a longer time until degraded, possibly through proteolysis. The remaining high level of mDPC even at 24 h after HN2 treatment hinted at the difficult removal of this cross-linked protein from DNA. To confirm that HN2 induced MGMT-DNA cross-link and its importance, MGMT siRNA was transfected before HN2 treatment (Supplementary Fig. 1B). As a result, the amounts of mDPC in MGMT–siRNA-delivered cells with or without HN2 treatment were comparable to normal control, but significantly lower than HN2-treated normal cells (Fig. 2D, E), confirming the preferential cross-linking of HN2 with MGMT as well as the methodological specificity for mDPC detection.

HR is important in DNA repair, involved in both DSB and DPC, especially in some cases when proteolysis is absent in DPC repair (Duxin et al., 2014; Stingele and Jentsch, 2015). In testing the expression of the representative genes of HR pathway in HN2 injury, FANCD2 (1.03 ± 0.02 vs. 0.35 ± 0.03) and its partner BRCA2 (1.10 ± 0.02 vs. 0.12 ± 0.00) showed obvious transcriptional upregulation (Fig. 3A), indicating the activation of the HR pathway. Although RAD51 transcription mildly increased (0.39 ± 0.03 vs. 0.23 ± 0.01), the RAD51 protein level remained unchanged at 0 h (0.32 ± 0.04), 1 h (0.28 ± 0.03), 6 h (0.28 ± 0.02), and 24 h (0.25 ± 0.02) (Fig. 3B), while the protein level of FANCD2 increased as well (data not shown). DVC1 is a protease newly predicted to play a special role in DPC repair, whose representative member Wss1 in yeast has been proven as a proteolytic enzyme in DPC repair. Here, for the first time, a dramatic upregulation of DVC1 mRNA was found as early as 1 h (0.93 ± 0.02) after HN2 exposure compared with the control (0.29 ± 0.01), and the upregulation was also shown at 24 h (1.19 ± 0.06) (Fig. 3C). For unknown reasons, there was a sharp decline of transcription at 6 h (0.42 ± 0.01). Correspondingly, the DVC1 protein level was increased moderately at 6 h (0.86 ± 0.02 vs. 0.29 ± 0.01) and significantly at 24 h (1.10 ± 0.04) (Fig. 3B). To address the effect of proteolysis on DPC repair, proteasome inhibitor MG132 was applied (Supplementary Fig. 1B). In MG132-treated normal cells, the basic level of tDPC increased, confirming the contribution of proteolysis to DPC cleavage. HN2 exposure led to tremendous tDPC formation, which was further enhanced by MG132 (Fig. 3D), suggesting proteolysis contributes to DPC degradation. When calculating the tDPC ratio before and after MG132 treatment in cells with or without HN2 insult, MG132 caused about 1.8-fold increase of tDPC in normal cultured cells and about a 1.2-fold increase in HN2-treated cells (Fig. 3D). However, the combined application of MG132 and HN2 induced about a 2.8-fold increase of mDPC above that in the control cells (180.61 ± 1.43 vs. 61.72 ± 3.01), and a further 1.6-fold elevation of mDPC above cells with HN2 treatment alone (180.61 ± 1.43 vs. 108.03 ± 5.12) (Fig. 3E). This data suggested that proteolysis could be rate-limited and could play a more important role in cleaving mDPC than tDPC. Because MG132 is not a DVC1-specific inhibitor, siRNA interference was used to knockdown DVC1 (Fig. 3F, Supplementary Fig. 1B), which caused more mDPC formation in cells with (135.11 ± 6.85 vs. 73.29 ± 4.05) or without (95.25 ± 4.96 vs. 62.53 ± 1.59) HN2 treatment (Fig. 3G), indicating a special role of DVC1-mediated proteolysis in mDPC removal.

Fig. 3. Proteolysis and HR take part in DNA repair. (A) The mRNA expression of HR-related genes after 50-μM HN2 exposure. (B) DVC1 and RAD51 protein level 1–24 h after HN2 exposure. (C) The mRNA expression of DVC1, a newfound protease in DPC repair, 1–24 h after HN2 exposure. (D) The amount of tDPC of MG132-treated and normal cells with or without HN2 exposure. * P b 0.05 vs. control. (E) The mDPC level induced by HN2 in the presence of MG132 or NMS-873. MG132 or NMS-873 were added for 3 h after HN2 exposure and then replaced by normal medium until 24 h. (F) DVC1 protein level after siRNA transfection with or without HN2 exposure. (G) The mDPC level when cell treated with or without si-DVC1 and HN2. (H) The comparison of tDPC amounts on NMS-873-treated cells and normal cells. * P b 0.05 vs. control.

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273

Considering that DVC1 can recruit and coordinate with protein p97 in DPC processing (Davis et al., 2012), the effect of the p97 inhibitor NMS-873 on DPC formation was tested. As expected, an elevation of about two to three times in both mDPC levels (189.44 ± 1.92 vs. 61.72 ± 3.01) (Fig. 3E) and tDPC (Fig. 3H) were clarified, providing supportive evidence for the special role of DVC1 in the cleavage of HN2caused tDPC and mDPC. 4.4. MGMT level influenced DNA repair Usually, MGMT promotes DNA repair, and cells with a deletion of MGMT may be more sensitive to DNA damage. According to the results of Western blot against γ-H2AX, it was shown that HN2 caused an increase of γ-H2AX in normal cells of 2.2- (0.77 ± 0.05 vs. 0.34 ± 0.01) and 1.8-fold (0.61 ± 0.05 vs. 0.34 ± 0.01) at 1 h and 24 h, respectively (P b 0.05). si-MGMT transfection per se caused about 1.8 times higher increase of H2AX as compared with normal cells (0.60 ± 0.01 vs. 0.34 ± 0.01), indicating the physiological necessity of MGMT. When cells are exposed to HN2, the γ-H2AX level increased further, but to a lesser extent than normal cell response, 1.2 (0.72 ± 0.02 vs.0.60 ± 0.01) and 1.4 (0.85 ± 0.05 vs. 0.60 ± 0.01) times at 1 h and 24 h respectively in si-MGMT transfected cells (Fig. 4A, B), which indicated that knockdown MGMT could, on the one hand, partially weaken the ability of DNA damage to repair normal cells, and on the other hand, supply fewer substrates for HN2 in the exposed cells to form mDPC and the consequent DSB. The protective effect of MGMT inhibition was confirmed. DVC1 expression could be augmented by HN2 exposure (Figs. 3B, C, and 4A), but knockdown of MGMT reduced DVC1 level in the presence of HN2 (Fig. 4A, C) at both 1 h (0.49 ± 0.01 vs. 0.60 ± 0.02) and 24 h (0.34 ± 0.02 vs. 0.60 ± 0.02), which suggested that DVC1 expression might partially be dependent on MGMT and/or the segregation of MGMT in mDPC. 5. Discussion In repairing alkylated DNA, the C-terminal domain of MGMT binds to DNA by intercalating a helix residue to the minor groove of DNA. The Nterminal domain, which contains a zinc finger, plays a function through tyrosine residue (Tyr114) bending the DNA chain and flipping out the O6-methylguanine base, which, in turn, allows the active site where Cys145 is located to transfer the alkyl base (Pegg, 2011). However, the situation is different in BAA-induced damage. BAAs can induce mDPC in two ways depending on their specific chemical constitution. As the predominant mechanism, BAAs react with cysteine in MGMT to form a highly reactive half-mustard, leaving one chloroethyl group active. Because of the DNA-binding property of MGMT, the MGMT–HN2 intermediate is likely to access DNA and thus cause a permanent covalent protein adduct, i.e., the MGMT-HN2-DNA cross-links (Liu et al., 2002). The alternative method is that BAAs interact with DNA first and then MGMT (Kalapila et al., 2009). BAAs, such as chlorambucil and HN2,

271

cross-link MGMT to DNA via Cys145 and Cys150. For single guanine conjugation, Cys145 may be a more active site (Loeber et al., 2008). Both of the two ways stabilize the transient interaction between MGMT and DNA during normal alkyl repair, and induced the permanent covalent cross-link. Our hypothesis was that the BAA-mediated anchorage of MGMT to DNA led to the dysfunction of MGMT and the bulky adduct mDPC itself created DNA damage, and as a result, MGMT became a DNA damage enhancer instead of the original important DNA repair enzyme. Our study demonstrated that MGMT was cross-linked with DNA, forming mDPC after HN2 treatment, and the dose- and time-effect relationship were unveiled. In Vlachostergios' report, tumor cells treated with the alkylating drug temozolomide (TMZ) did not show nuclear MGMT reduction, while proteasome inhibitor bortezomib (BZ) alone or in combination with TMZ caused a significant suppression (Vlachostergios et al., 2013). In our HN2-treated cells, the expression of MGMT was suppressed while the mDPC formation in the nuclear compartment dramatically increased, a situation different from the mono-alkylating agent TMZ. Although the formation and toxicity of DPC is theoretically acceptable, it is difficult to evaluate the specific role of DPC and its repair enzyme MGMT in the cytotoxic and mutagenic effects because DPCs are estimated to constitute only 1%–3% of total DNA damage when cells are exposed to bis-electrophiles and ionizing radiation (Tretyakova et al., 2013). Two promising advances have been made recently: one is the isolation and detection of trace amount of DPCs, including MGMTconstituted DPC (Shoulkamy et al., 2012; Kiianitsa and Maizels, 2013); another is the confirmation of Wss1-mediated proteolysis in DPC cleavage in yeast (Stingele et al., 2014) followed by the proposed ortholog candidate DVC1 in mammalians (Davis et al., 2012; Stingele et al., 2015). DPC is a lethal type of DNA damage different from intrastrand or interstrand cross-link, SSB, and DSB. As a standard DPC-inducing agent, formaldehyde is widely studied. Using LC-MS/MS, Qin found formaldehyde can cross-link N 100 DNA-binding proteins, which are involved mainly in transcription, gene regulation, and DNA replication and repair (Qin and Wang, 2009). The result can be easily understood, because normally the transient DNA–protein interactions are common and necessary for the above events, which provide more opportunity for formaldehyde to react (Stingele and Jentsch, 2015). For unknown reasons, MGMT was undetected in that report. Compared with formaldehyde, HN2 cross-links fewer proteins including MGMT (only 38 kinds of proteins), of which 22 proteins are the same as formaldehyde cross-linked (Michaelson-Richie et al., 2011). So, the cross-linking sites and processes between formaldehyde and HN2 are quite different (Michaelson-Richie et al., 2011; Stingele and Jentsch, 2015). Our study identified MGMT as an important contributor to HN2-induced DPC, and the time- and dose-effect relationship was elucidated for the first time. The HN2 dose-dependent formation of mDPC and/or other types of DNA alkylation may preferentially recruit more MGMT to the damaged sites of DNA and facilitate more mDPC formation. This is an instant chemical reaction completed within a short time; a high level of mDPC was reached at 1 h after HN2 treatment and remained at the high level

Fig. 4. MGMT level influences DNA repair. (A) The γ-H2AX and DVC1 levels in HN2-treated 16HBE were resolved by Western blot in MGMT-knockdown cells and normal cells. (B) γ-H2AX expression between si-MGMT transfected cells and normal cell at different times after 50-μM HN2 exposure. * P b 0.05 vs. control. (C) DVC1 protein expression in 16HBE 1 and 24 h after HN2 exposure with or without MGMT knockdown. * P b 0.05 vs. control.

272

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273

up to 24 h, suggesting that the cleavage of mDPC was not efficient in cells. By contrast, natural cellular MGMT was almost completely diminished, possibly due to the formation of mDPC, protein ubiquitination, and degradation. We were also aware that mRNA expression of MGMT was significantly upregulated at 6 h preceded by suppression at 1 h, whereas other parameters of DNA damage and repair including tDPC (Fig. 1A), mDPC (Fig. 2C), γ-H2AX (Fig. 1B), and DVC1 mRNA (Fig. 3C) inversely fell back at 6 h between 1 h and 24 h. At 1 h after HN2 injury, the increased formation of DPC, DNA alkylation, and DSB, which invoked H2AX phosphorylation, could initiate a quick MGMT translocation into the nuclear compartment and, unfortunately, formed mDPC. A sharp increase of tDPC activated the transcription of DVC1. Considering the significant inhibition of MGMT at this time point, we assumed that there might be an inhibitory feedback when a high enough MGMT level in the nuclear compartment was sensed by certain mechanism. For example, IκBα-mediated proteasome-dependent nuclear accumulation of NF-κB has been identified as a major regulator of MGMT expression (Vlachostergios et al., 2013). At 6 h with the gradual degradation of mDPC and repair of DNA break, a declined MGMT level in the nuclear compartment and the presence of DNA alkylation would stimulate MGMT expression. Meanwhile, the decreased DPC level as well as the initially upregulated DVC1 expression signaled a dramatic downregulation of DVC1. We noticed a continued increase of γ-H2AX at 24 h that indicated more DNA strand breaks occurred, which could be caused by MGMT-mediated alkyl group transfer, monoadduct-induced apurination and DPC cleavage. Consistently, the remaining of high DPC level at 24 h also meant potential DNA breaks and γ-H2AX in the following repair process even after this time point. However, our proposed mechanism needs be proved experimentally. Because of the complexity of DNA damage and its repair, several pathways are candidates in HN2-induced DPC repair. Considering the 23 kDa molecular weight of MGMT, NER may be ineffective for MGMT-adduct removal. This presumption is supported by that the mRNA level of ERCC1, a core gene in NER pathway, did not change (data not shown), while FANCD2 and BRCA2 were upregulated, suggesting the activation of HR pathway. Stingele established a systemic model of DPC repair, which described two solutions for coping with DPC (Stingele et al., 2015; Stingele and Jentsch, 2015). Bulky protein component is broken-down by proteolysis via DPC protease, which allows replication progress. It has be proven that the proteolysis is nonspecific in yeast, because Wss1 targets any protein substrate that is conjugated on the DNA strand but does not discriminate the exact type of the substrate (Stingele and Jentsch, 2015). However, remaining peptide may lead to translesion synthesis (TLS) and then cause mutagenesis. In addition, when cells are deficient in DPC repair, replication stress may cause DSB. Under these conditions, HR is needed for DPC tolerance, although unrepaired DPC may induce genome rearrangements and instability (Stingele et al., 2015; Stingele and Jentsch, 2015). Usually, the cross– linking-disabled MGMT is degraded by ubiquitination (Pegg, 2011). Coincidently, mammalian DVC1, the ortholog of yeast Wss1, possesses an interaction domain for either ubiquitin or small ubiquitin-like modifier (SUMO) near the C-terminal (Stingele et al., 2015). However, the exact function of DVC1 in DPC repair has not been confirmed experimentally. In the present study, we tried to elucidate the role of DVC1 in HN2-induced DPC repair. Fortunately, it was proven that DVC1 indeed plays a key role in the repair of both tDPC and mDPC in a p97-dependent manner. HN2 exposure induced DVC1 upregulation of transcription starting from 1 h and of translation from 6 h. Inhibition of proteasome promoted moderate tDPC formation and robust mDPC formation after HN2 injury. DVC1 knockdown induced a higher mDPC level in normal culture and even more mDPC formation when inflicted with HN2. All these data suggested the upregulation of DVC1 is preferentially important for the cleavage of mDPC. The localization of DVC1 to sites of DNA damage requires the ability of the DVC1 UBZ domain to bind to ubiquitin polymers and a conserved PCNA-interacting motif (Davis et al., 2012). It is newly

identified that p97 facilitates the extraction of TLS polymerase (Pol) η, and a highly speculative possibility is that DVC1 degrades proteins after release from sites of DNA damage by p97 (Davis et al., 2012). At the present stage, we confirmed the necessity of p97 in processing mDPC, but it is still not known if ubiquitylation and subsequent segregation of mDPC are necessary before proteolysis by DVC1 and degradation by proteasome, which is worthy of further investigation. Based on our data, we speculated that, as a bridge, HN2 preferentially caused DNA damage-recruited MGMT to stably and covalently crosslink with DNA. In this process, MGMT was disabled for its normal function and turned from an alkyl group transferase to a DNA damage participator. The present study demonstrated that DVC1 is an important protease in mDPC cleavage in a p97-dependent manner. We proposed that MGMT is not always a drug resistance factor for alkylating chemotherapeutic drugs, and that the mDPC level may be used to test tumor cell sensitivity to alkylating drugs before chemotherapy is started. However, many details of the mechanisms remain unclear, such as the proteolysis and HR interaction in HN2-induced DPC repair and the ubiquitination procedure of MGMT mediated by DVC1. Further studies should focus on these aspects so as to reveal the entire mechanism of HN2-induced DNA-MGMT cross-link. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.taap.2016.06.022. Conflicts of interest The authors declare no conflict of interest. Grant support Natural Science Foundation of China (81302862). References Barker, S., Weinfeld, M., Murray, D., 2005. DNA-protein crosslinks: their induction, repair, and biological consequences. Mutat. Res. 589, 111–135. Cabrini, G., Fabbri, E., Lo Nigro, C., Dechecchi, M.C., Gambari, R., 2015. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (review). Int. J. Oncol. 47, 417–428. Casorelli, I., Bossa, C., Bignami, M., 2012. DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias. Int. J. Environ. Res. Public Health 9, 2636–2657. Davis, E.J., Lachaud, C., Appleton, P., Macartney, T.J., Nathke, I., Rouse, J., 2012. DVC1 (C1orf124) recruits the p97 protein segregase to sites of DNA damage. Nat. Struct. Mol. Biol. 19, 1093–1100. de Graaf, B., Clore, A., McCullough, A.K., 2009. Cellular pathways for DNA repair and damage tolerance of formaldehyde-induced DNA-protein crosslinks. DNA Repair (Amst) 8, 1207–1214. Duxin, J.P., Dewar, J.M., Yardimci, H., Walter, J.C., 2014. Repair of a DNA-protein crosslink by replication-coupled proteolysis. Cell 159, 346–357. Ide, H., Shoulkamy, M.I., Nakano, T., Miyamoto-Matsubara, M., Salem, A.M., 2011. Repair and biochemical effects of DNA-protein crosslinks. Mutat. Res. 711, 113–122. Kalapila, A.G., Pegg, A.E., 2010. Alkyltransferase-mediated toxicity of bis-electrophiles in mammalian cells. Mutat. Res. 684, 35–42. Kalapila, A.G., Loktionova, N.A., Pegg, A.E., 2009. Effect of O6-alkylguanine-DNA alkyltransferase on genotoxicity of epihalohydrins. Environ. Mol. Mutagen. 50, 502–514. Kiianitsa, K., Maizels, N., 2013. A rapid and sensitive assay for DNA-protein covalent complexes in living cells. Nucleic Acids Res. 41, e104. Kisby, G.E., Olivas, A., Park, T., Churchwell, M., Doerge, D., Samson, L.D., Gerson, S.L., Turker, M.S., 2009. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst) 8, 400–412. Liu, L., Pegg, A.E., Williams, K.M., Guengerich, F.P., 2002. Paradoxical enhancement of the toxicity of 1,2-dibromoethane by O6-alkylguanine-DNA alkyltransferase. J. Biol. Chem. 277, 37920–37928. Loeber, R., Rajesh, M., Fang, Q., Pegg, A.E., Tretyakova, N., 2006. Cross-linking of the human DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in the presence of 1,2,3,4-diepoxybutane. Chem. Res. Toxicol. 19, 645–654. Loeber, R., Michaelson, E., Fang, Q., Campbell, C., Pegg, A.E., Tretyakova, N., 2008. Crosslinking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem. Res. Toxicol. 21, 787–795. Loeber, R.L., Michaelson-Richie, E.D., Codreanu, S.G., Liebler, D.C., Campbell, C.R., Tretyakova, N.Y., 2009. Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem. Res. Toxicol. 22, 1151–1162.

J. Cheng et al. / Toxicology and Applied Pharmacology 305 (2016) 267–273 Michaelson-Richie, E.D., M., X., Codreanu, S.G., Loeber, R.L., Liebler, D.C., Campbell, C., Tretyakova, N.Y., 2011. Mechlorethamine-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells. J. Proteome Res. 10, 2785–2796. Nakano, T., Morishita, S., Katafuchi, A., Matsubara, M., Horikawa, Y., Terato, H., Salem, A.M., Izumi, S., Pack, S.P., Makino, K., Ide, H., 2007. Nucleotide excision repair and homologous recombination systems commit differentially to the repair of DNA-protein crosslinks. Mol. Cell 28, 147–158. Pegg, A.E., 2011. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem. Res. Toxicol. 24, 618–639. Qin, H., Wang, Y., 2009. Exploring DNA-binding proteins with in vivo chemical crosslinking and mass spectrometry. J. Proteome Res. 8, 1983–1991. Shoulkamy, M.I., Nakano, T., Ohshima, M., Hirayama, R., Uzawa, A., Furusawa, Y., Ide, H., 2012. Detection of DNA-protein crosslinks (DPCs) by novel direct fluorescence labeling methods: distinct stabilities of aldehyde and radiation-induced DPCs. Nucleic Acids Res. 40, e143. Srivenugopal, K.S., Rawat, A., Niture, S.K., Paranjpe, A., Velu, C., Venugopal, S.N., Madala, H.R., Basak, D., Punganuru, S.R., 2016. Posttranslational regulation of O(6)methylguanine-DNA methyltransferase (MGMT) and new opportunities for treatment of brain cancers. Mini Rev. Med. Chem. 16, 455–464.

273

Stingele, J., Jentsch, S., 2015. DNA-protein crosslink repair. Nat. Rev. Mol. Cell Biol. 16, 455–460. Stingele, J., Schwarz, M.S., Bloemeke, N., Wolf, P.G., Jentsch, S., 2014. A DNA-dependent protease involved in DNA-protein crosslink repair. Cell 158, 327–338. Stingele, J., Habermann, B., Jentsch, S., 2015. DNA-protein crosslink repair: proteases as DNA repair enzymes. Trends Biochem. Sci. 40, 67–71. Tretyakova, N.Y., Michaelson-Richie, E.D., Gherezghiher, T.B., Kurtz, J., Ming, X., Wickramaratne, S., Campion, M., Kanugula, S., Pegg, A.E., Campbell, C., 2013. DNA-reactive protein monoepoxides induce cell death and mutagenesis in mammalian cells. Biochemistry 52, 3171–3181. Ueda, S., Mineta, T., Nakahara, Y., Okamoto, H., Shiraishi, T., Tabuchi, K., 2004. Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas. J. Neurosurg. 101, 659–663. Vlachostergios, P.J., Hatzidaki, E., Befani, C.D., Liakos, P., Papandreou, C.N., 2013. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Investig. New Drugs 31, 1169–1181. Wong, V.C., Cash, H.L., Morse, J.L., Lu, S., Zhitkovich, A., 2012. S-phase sensing of DNA-protein crosslinks triggers TopBP1-independent ATR activation and p53-mediated cell death by formaldehyde. Cell Cycle 11, 2526–2537.